Agmatine
Names | |
---|---|
IUPAC name
1-(4-Aminobutyl)guanidine[1]
| |
Identifiers | |
3D model (
JSmol ) |
|
3DMet | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard
|
100.005.626 |
EC Number |
|
KEGG | |
MeSH | Agmatine |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C5H14N4 | |
Molar mass | 130.195 g·mol−1 |
Density | 1.2 g/ml |
Melting point | 102 °C (216 °F; 375 K) |
Boiling point | 281 °C (538 °F; 554 K) |
high | |
log P | −1.423 |
Basicity (pKb) | 0.52 |
Hazards | |
Flash point | 95.8 °C (204.4 °F; 368.9 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Agmatine, also known as 4-aminobutyl-guanidine, was discovered in 1910 by Albrecht Kossel.[2] It is a chemical substance which is naturally created from the amino acid arginine. Agmatine has been shown to exert modulatory action at multiple molecular targets, notably: neurotransmitter systems, ion channels, nitric oxide (NO) synthesis and polyamine metabolism and this provides bases for further research into potential applications.
History
The term agmatine stems from A- (for
Metabolic pathways
Agmatine biosynthesis by arginine decarboxylation is well-positioned to compete with the principal arginine-dependent pathways, namely: nitrogen metabolism (urea cycle), and polyamine and nitric oxide (NO) synthesis (see illustration 'Agmatine Metabolic Pathways'). Agmatine degradation occurs mainly by hydrolysis, catalyzed by agmatinase into urea and putrescine, the diamine precursor of polyamine biosynthesis. An alternative pathway, mainly in peripheral tissues, is by diamine oxidase-catalyzed oxidation into agmatine-aldehyde, which is in turn converted by aldehyde dehydrogenase into guanidinobutyrate and secreted by the kidneys.
Mechanisms of action
Agmatine was found to exert modulatory actions directly and indirectly at multiple key molecular targets underlying cellular control mechanisms of cardinal importance in health and disease. It is considered capable of exerting its modulatory actions simultaneously at multiple targets.[8] The following outline indicates the categories of control mechanisms and identifies their molecular targets:
- Neurotransmitter receptors and receptor ionophores. Nicotinic, imidazoline I1 and I2, α2-adrenergic, glutamate NMDAr, and serotonin 5-HT2A and 5HT-3 receptors.
- Ion channels. Including: ATP-sensitive K+ channels, voltage-gated Ca2+ channels, and acid-sensing ion channels (ASICs).
- Membrane transporters. Agmatine specific-selective uptake sites, organic cation transporters (mostly OCT2 subtype), extraneuronal monoamine transporters (ENT), polyamine transporters, and mitochondrial agmatine specific-selective transport system.
- Nitric oxide (NO) synthesis modulation. Both differential inhibition and activation of NO synthase (NOS) isoforms is reported.[9][10]
- Polyamine metabolism. Agmatine is a precursor for polyamine synthesis, competitive inhibitor of polyamine transport, inducer of spermidine/spermine acetyltransferase (SSAT), and inducer of antizyme.
- Protein ADP-ribosylation. Inhibition of protein arginine ADP-ribosylation.
- Matrix metalloproteases(MMPs). Indirect down-regulation of the enzymes MMP 2 and 9.
- Advanced glycation end product(AGE) formation. Direct blockade of AGEs formation.
- NADPH oxidase. Activation of the enzyme leading to H2O2 production.[11]
Food consumption
Agmatine sulfate injection can increase food intake with carbohydrate preference in satiated, but not hungry, rats and this effect may be mediated by neuropeptide Y.[12] However, supplementation in rat drinking water results in slight reductions in water intake, body weight, and blood pressure.[13] In addition, force feeding with agmatine leads to a reduction in body weight gain during rat development.[14] It is also found that many fermented foods contain agmatine.[15][16]
Pharmacokinetics
Agmatine is present in small amounts in plant-, animal-, and fish-derived foodstuff and gut microbial production is an added source for agmatine. Oral agmatine is absorbed from the gastrointestinal tract and readily distributed throughout the body.[17] Rapid elimination from non-brain organs of ingested (un-metabolized) agmatine by the kidneys has indicated a blood half life of about 2 hours.[18]
Research
A number of potential medical uses for agmatine have been suggested.[19]
Cardiovascular
Agmatine produces mild reductions in heart rate and blood pressure, apparently by activating both central and peripheral control systems via modulation of several of its molecular targets including: imidazoline receptors subtypes, norepinephrine release and NO production.[20]
Glucose regulation
Agmatine hypoglycemic effects are the result of simultaneous modulation of several molecular mechanisms involved in blood glucose regulation.[8]
Kidney functions
Agmatine has been shown to enhance glomerular filtration rate (GFR) and to exert nephroprotective effects.[21]
Neurotransmission
Agmatine has been discussed as a putative
Due to its ability to pass through open cationic channels, agmatine has also been used as a surrogate metric of integrated ionic flux into neural tissue upon stimulation.[24] When neural tissue is incubated in agmatine and an external stimulus is applied, only cells with open channels will be filled with agmatine, allowing identification of which cells are sensitive to that stimuli and the degree to which they opened their cationic channels during the stimulation period.
Opioid liability
Systemic agmatine can potentiate opioid analgesia and prevent tolerance to chronic morphine in laboratory rodents. Since then, cumulative evidence amply shows that agmatine inhibits opioid dependence and relapse in several animal species.[25]
See also
References
- ^ "agmatine (CHEBI:17431)". Chemical Entities of Biological Interest. UK: European Bioinformatics Institute. 15 August 2008. Main. Retrieved 11 January 2012.
- .
- ^ "agmantine". Oxford English Dictionary (Online ed.). Oxford University Press. (Subscription or participating institution membership required.)
- .
- PMID 16993089.
- S2CID 35090913.
- PMID 7906055.
- ^ PMID 23769988.
- PMID 8645212.
- PMID 23994446.
- S2CID 16298942.
- PMID 21564088.
- PMID 24140462.
- PMID 24523404.
- PMID 22701114.
- ^ Wang, Che-Chuan. "Beneficial Effect of Agmatine on Brain Apoptosis, Astrogliosis, and Edema after Rat Transient Cerebral Ischemia." BMC Pharmacology. BioMed Central, 6 Sept. 2010. Web. 03 Mar. 2016.
- PMID 18832451.
- PMID 20586417.
- PMID 17927294.
- PMID 11454649.
- S2CID 23116711.
- S2CID 20785398.
- S2CID 32456961.
- S2CID 15955446.
- PMID 12852826.
Further reading
- Wilcox G, Fiska A, Haugan F, Svendsen F, Rygh L, Tjolsen A, Hole K (2004). "Central sensitization: The endogenous NMDA antagonist and NOS inhibitor agmatine inhibits spinal long term potentiation (LTP)". The Journal of Pain. 5 (3): S19. .